Intellia’s first CRISPR gene editing therapy shows promise in small study

Dr. Vaishali Sanchorawala, director of the Amyloidosis Center at Boston Medical Center, said that longer-term follow up of the patients will be needed to see if the treatment can eventually reverse organ damage caused by the disease, but she is encouraged by the results so far.

Intellia’s first CRISPR gene editing therapy shows promise in small study